StockData
Sinovac Biotech Ltd logo

Sinovac Biotech Ltd (SVA) income statement

SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Jun 5, 2026Score 7/30
$6.47+0.00 (0.00%)

Close on Nov 18, 2026Market cap $464.94MP/E –Yield 850.08%

Sinovac Biotech Ltd income statement

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin
67.9%
Operating margin
-127.0%
Net margin
–
Return on equity, FY2025
–

Financial strength

Current ratio
4.59
Debt to equity
–
Debt to assets
–
Cash to current liabilities
31.7%

Valuation

P/E ratio
–
Price to sales
1.20
Price to book
0.10
Dividend yield
850.08%

See a number that looks wrong?